Profile data is unavailable for this security.
About the company
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
- Revenue in USD (TTM)3.22bn
- Net income in USD348.90m
- Incorporated1996
- Employees3.22k
- LocationBioMarin Pharmaceutical Inc770 Lindaro StreetSAN RAFAEL 94901United StatesUSA
- Phone+1 (415) 506-6700
- Fax+1 (302) 636-5454
- Websitehttps://www.biomarin.com/
Mergers & acquisitions
| Acquired company | BMRN:NSQ since announced | Transaction value |
|---|---|---|
| Amicus Therapeutics Inc | 12.67% | 4.79bn |
| Inozyme Pharma Inc | 0.45% | 274.36m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc | 189.76m | -201.92m | 6.12bn | 414.00 | -- | 43.28 | -- | 32.23 | -3.11 | -3.11 | 2.92 | 4.02 | 0.435 | 0.8762 | 8.51 | 458,350.30 | -45.05 | -50.41 | -60.38 | -61.35 | 89.73 | 89.41 | -103.57 | -210.46 | 4.16 | -36.30 | 0.286 | -- | 45.83 | -- | 23.68 | -- | 34.81 | -- |
| Krystal Biotech Inc | 389.13m | 204.83m | 7.71bn | 295.00 | 38.56 | 6.31 | 36.62 | 19.82 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
| Halozyme Therapeutics, Inc. | 1.40bn | 316.89m | 8.19bn | 423.00 | 27.85 | 167.45 | 20.22 | 5.86 | 2.49 | 2.49 | 11.38 | 0.4144 | 0.6087 | 1.44 | 3.73 | 3,301,681.00 | 13.81 | 19.86 | 14.83 | 21.98 | 83.62 | 81.56 | 22.69 | 37.92 | 3.66 | -- | 0.9777 | 0.00 | 37.55 | 39.16 | -28.64 | 19.68 | 159.51 | -- |
| Axsome Therapeutics Inc | 638.50m | -183.17m | 8.39bn | 925.00 | -- | 94.54 | -- | 13.14 | -3.69 | -3.69 | 12.84 | 1.74 | 1.01 | 2.17 | 3.48 | 690,265.90 | -29.11 | -51.00 | -56.42 | -77.57 | 92.56 | -- | -28.69 | -76.38 | 1.48 | -25.78 | 0.6878 | -- | 65.55 | -- | 36.22 | -- | 59.92 | -- |
| Biomarin Pharmaceutical Inc | 3.22bn | 348.90m | 11.26bn | 3.22k | 32.85 | 1.85 | 26.27 | 3.49 | 1.78 | 1.78 | 16.57 | 31.65 | 0.4418 | 0.4726 | 4.11 | 1,000,079.00 | 4.79 | 3.09 | 5.28 | 3.46 | 81.43 | 78.42 | 10.83 | 8.18 | 3.50 | -- | 0.0893 | 0.00 | 12.87 | 11.60 | -18.26 | 138.08 | -4.20 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 11.49bn | 2.80k | -- | 2.86 | 36.16 | 2.76 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Elanco Animal Health Inc | 4.72bn | -232.00m | 12.37bn | 9.40k | -- | 1.89 | 27.61 | 2.62 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| BridgeBio Pharma Inc | 502.08m | -724.93m | 12.51bn | 834.00 | -- | -- | -- | 24.92 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 13.16bn | 2.00k | 28.12 | 4.04 | 25.87 | 4.60 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 16.67m | 8.68% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 16.25m | 8.46% |
| Dodge & Coxas of 31 Dec 2025 | 14.57m | 7.59% |
| PRIMECAP Management Co.as of 31 Dec 2025 | 14.55m | 7.57% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 7.53m | 3.92% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 7.52m | 3.92% |
| AQR Capital Management LLCas of 31 Dec 2025 | 6.69m | 3.48% |
| Viking Global Investors LPas of 31 Dec 2025 | 6.04m | 3.14% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.67m | 1.91% |
| Millennium Management LLCas of 31 Dec 2025 | 3.04m | 1.58% |
